lucorafusp alfa (AK130) / Akesobio - LARVOL DELTA

A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC). (clinicaltrials.gov) - P1/2 | N=280 | Not yet recruiting | Sponsor: Akeso

Combination therapy • Metastases • New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

A Study of AK130 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=19 | Completed | Sponsor: Akeso | Not yet recruiting ➔ Completed | N=72 ➔ 19 | Trial completion date: Jan 2025 ➔ May 2024

Enrollment change • Metastases • Trial completion • Trial completion date • Oncology • Solid Tumor

A Study of AK130 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Akeso

Metastases • New P1 trial • Oncology • Solid Tumor

First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO (PRNewswire) - "The encouraging observations from preclinical results of AK130 supports its clinical development for the treatment of human cancers: AK130 could specifically bind to human TIGIT and TGF-β with high affinity. In reporter gene assays, AK130 efficiently blocked the interaction between TIGIT and CD155, as well as TGF-β1/TGF-β3 and TGFβ-RII. As expected, AK130 did not show ADCC or CDC activity compared to tiragolumab. AK130 shows great anti-tumor efficacy in a mouse tumor model."

Preclinical • Oncology